Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Drug Disease Crizotinib Non-SmallCell Lung Carcinoma Cetuximab Head and Neck Cancers Pemetrexed Non-SmallCell Lung Carcinoma Dasatinib Dasatinib Chronic Myeloid Leukaemia Chronic Myeloid Leukaemia Indication In second and subsequent line anaplastic lymphoma kinase (ALK)-positive advanced nonsmall lung cancer 1st line treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck Maintenance treatment of stage IIIB/IV nonsquamous nonsmall cell lung cancer after response to pemetrexedcontaining first line therapy Treatment of CML which is refractory or significant intolerance to imatinib and intolerance to nilotinib Untreated CML Status Publication date 12 month cost impact Published Dec-16 (<£1m p/a 100 for England) Mar-17 Not recommended in Appraisal Consultation Document (ACD) (published January 2017) Aug-16 £6.3m (based on list price). Around 690 eligible and 570 estimated to take up treatment each year. Dec-16 £3.7m based on list price and assumption that number of people treated increases from 430 to 550. 550 Dec-16 Around 530 people per year (<£1m p/a eligible to start for England) 1st line treatment each year. In developm ent Published Published Published Population in first 12 months Sorafenib Trastuzumab Emtansine Radium 223 Ibrutinib Cabazitaxel Brentuximab Hepatocellu lar carcinoma (HCC) 1st line HCC In developm ent Mar-17 Not available Breast Cancer Treatment of HER2-positive locally advanced/unrese ctable or metastatic (Stage IV) breast cancer who previously received trastuzumab and a taxane, separately or in combination In developm ent Mar-17 Not recommended at appraisal (published Jan '17) Prostate Cancer Treatment of hormonerelapsed prostate cancer patients with bone metastases Published Sep-16 £9.0m Lymphoma Treatment of relapsed/ refractory mantle cell lymphoma In developm ent To be confirmed Not recommended at appraisal (published Jan '17) Prostate Cancer 2nd or 3rd line metastatic castration resistant prostate cancer Published May-16 Not avilable Lymphoma Treatment of relapsed/ refractory In anaplastic large developm cell lymphoma ent where no other salvage treatment is available May-17 Not recommended at appraisal (published Dec '16) Data not yet available 360 370